SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 07:00 ET
|
Scynexis
SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME® (ibrexafungerp tablets). SCYNEXIS will receive an upfront...
SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark
April 13, 2023 08:30 ET
|
Scynexis
JERSEY CITY, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 31, 2023 08:30 ET
|
Scynexis
SCYNEXIS announced it has signed an exclusive agreement with GSK to commercialize and further develop BREXAFEMME® (ibrexafungerp tablets) for all indications. GSK will make an upfront payment to...
GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection
March 30, 2023 07:05 ET
|
Scynexis
Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with...
SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
December 01, 2022 08:00 ET
|
Scynexis
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent VVC. ...
SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi
November 30, 2022 08:30 ET
|
Scynexis
Researchers to study the potential of SCY-247 to fight Candida auris (C.auris), a multidrug-resistant pathogen named as an “urgent threat” by the Centers for Disease Control (CDC) and included in the...
SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats
November 17, 2022 08:30 ET
|
Scynexis
BARDA is seeking to support the development of broad-spectrum, oral/IV antifungal drug candidates with novel mechanisms of action that target Candida species, including Candida auris, and Aspergillus...
SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022 07:00 ET
|
Scynexis
SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications.Ivor Macleod, a 30-year biopharma...
SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi
November 07, 2022 08:30 ET
|
Scynexis
JERSEY CITY, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Women’s Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection
November 03, 2022 08:30 ET
|
Scynexis
Clinical cure rates, in the pooled analysis, were statistically significantly greater for ibrexafungerp when compared with placebo (p < 0.0001). In the pooled analysis, patients receiving...